1. OPTIDUAL
Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with clopidogrel vs. 36 months of aspirin monotherapy.
Results
(p = 0.17)
All-cause death, MI, stroke, or major bleeding: 5.8% of the 48-month DAPT group vs. 7.5% of the 12-month DAPT group (p = 0.17)
Death, MI, or stroke: 4.2% in the 48-month DAPT group vs. 6.4% in the 12-month DAPT group (p = 0.06)
Bleeding: 2.0% in both groups (p = 0.95) %
7.5
5.8
Conclusions
Among patients who received a drug-eluting stent and were event-free at 12 months, ischemic outcomes were nonsignificantly reduced with extended duration of DAPT (clopidogrel) for an additional 36 months
Additional 36 months of DAPT
Aspirin monotherapy
Presented by Dr. Gerard Helft at ESC 2015